Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options

Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options

Abstract Background Being the standard-of-care for four decades, cisplatin-based chemotherapy is highly efficient in treating germ cell tumors (GCT). However, often refractory patients present with a remaining (resistant) yolk-sac tumor (YST(-R)) component, resulting in poor prognosis due to lack of...

Full description

Bibliographic Details
Main Authors: Margaretha A. Skowron, Mara Kotthoff, Felix Bremmer, Katja Ruhnke, Fatma Parmaksiz, Annika Richter, Stefan Küffer, Kirsten Reuter-Jessen, Stella Pauls, Anja Stefanski, Philipp Ströbel, Kai Stühler, Daniel Nettersheim
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Molecular Medicine
Subjects:
Germ cell tumors
Yolk-sac tumor
Therapy
Resistance
CLDN6
Antibody-drug-conjugate
Online Access:https://doi.org/10.1186/s10020-023-00636-3

Internet

https://doi.org/10.1186/s10020-023-00636-3

Similar Items